Craig-Hallum analyst Bill Bonello notes that two payors, namely Health Care Service Corporation, or HCSC, and Florida Blue posted updated Medical Policies indicating that Exact Sciences' Cologuard may be "medically necessary" for colorectal cancer screening. The analyst believes this is a "very positive" indicator of how other payors will interpret the positive recommendation from the U.S. Preventive Services Task Force issued in June. Further, he sees Exact Sciences as well positioned to become standard of care for colon cancer screening, which could be a $3B-$5B opportunity over time. Bonello reiterates a Buy rating and $26 price target on the shares.